NEXALIN TECHNOLOGY ANNOUNCES UCSD IRB APPROVAL FOR USE OF HALO™ CLARITY IN CLINICAL TRIALS FOR MTBI AND PTSD TREATMENT
Source text: ID:nGNX3pt1ml
Further company coverage: NXL.O
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.